Dealmakers Newsletter Update: P&A the new M&A?

Sponsored this month by:

Never Before Has Partnering and Licensing Been So Important

The 2009 BIO International Convention travels to Atlanta, Georgia, May 18–21, 2009.

Join 20,000 executives, investors, scientists, researchers, policy makers and journalists from around the world for strategic discussions on new business models and new opportunities in biotech. Access the expert knowledge and resources you need to meet the challenges of today’s dynamic economy and to strengthen your business for tomorrow. Come together with the industry to explore collaborations that will deliver on the promise of biotech to heal, fuel, feed the world.

Registration and Housing Now Open. http://convention.bio.org

Editor's corner Partnering roundup In the news Best practice articles Forthcoming events New reports this month On the move

Editor's corner

Welcome to the new-look Dealmakers newsletter from CurrentPartnering.

Partnering and M&A deals to continue to dominate the news as companies seek to raise funds and shore up pipelines.

A recent article at SeekingAlpha suggests the industry should be thinking P&A instead of M&A, in other words partnerships and acquisition to provide access to pipeline candidates, possibly with options to acquire later on.

The article can be viewed at: SeekingAplha

Our industry round-up and in the news sections below provide additional updates on partnering and M&A activity.

March is also the start of the new 'partnering event season, with numerous events including BioEurope Spring, EuroPLX and BioWindhover in quick succession, followed by arguably the biggest partnering event of them all: BIO2009 Convention Business Forum. These are the places where deals will be done this spring, so if you are seeking partners get yourself booked in now - details of each event below.

Finally we have updated our M&A report to reflect this latest activity, incorporating deals up to and including end 2008 - more details below. In addition, we have updated our co-promotion/co-marketing report. These join our ever expanding list of titles. We will be publsihing a number of new titles shortly - watch this space!

All for now

-- Steve Poile --

Partnering roundup

Predictions for 2009 amidst the credit crisis have been published recently:

• Does the U.S. biotech industry deserve a bailout?
• The Biotech Bailout: Why saving the industry means saving lives
• Steven Burrill predicts what’s ahead for biotech in 2009
• Top 10 biotech events to watch

Whilst elsewhere bigpharma is on the prowl for product/company acquisitions:

• Pharma buying spree could swallow biotechs
• Genzyme on the hunt for new products
• Big drug makers may seek to fill holes in roster
• Alternatives to mega-mergers
• Pharma’s ongoing quest for R&D innovation
• Merck plans data sharing platform for disease biology

In the news

2009 conitues to be filled with M&A announcements:

• Merck to buy Schering-Plough for $41.1 billion
• Roche expected to seal Genentech deal after upping bid
• Lundbeck to buy OVATION Pharmaceuticals

Other deals of note so far in March 2009:

• Teikoku and Eisai in licensing agreement for new 7-Day transdermal formulation of Donepezil
• Evotec and Roche to develop EVT 101 for treatment-resistant depression
• Proteros biostructures in collaboration with UCB
• AEterna Zentaris and Sanofi-Aventis in development, commercialization and licensing agreement for Cetrorelix in benign prostatic hyperplasia
• Bristol-Myers Squibb enters global collaboration with Nissan Chemical Industries and Teijin Pharma on novel atrial fibrillation compound
• Pfizer to license generics from Aurobindo Pharma
• Pfizer and Bausch & Lomb to promote eye drugs
• Xencor and Pfizer in antibody technology licensing agreement

Keep posted on the latest deals and alliances with CurrentPartnering's In the news feature

New reports this month

Revised and updated reports:

CurrentPartnering has revised and updated its most popular reports:

Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition

The Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition report provides comprehensive understanding and unprecedented access to the merger and acquisition (M&A) agreements entered into by the worlds leading biopharma companies

More details and order

Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 2nd edition

The Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 2nd edition

More details and order

New report:

CurrentPartnering has launched its latest report:

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

The Royalty Financing Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.

More details and order

New from Datamonitor:

Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape

Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines

More details and order

Best practice articles

EuroPLX Enters 15th Great Year of Facilitating Pharma Deals

With its 40th Meeting forthcoming in June, EuroPLX® (short for European Pharma License Exchange) will enter its 15th year of facilitating pharma deals in the worldwide pharmaceutical and biotech industries read more

Biosimilars in the EU: delivering the goods?

In January, leading pharmaceutical experts attended the 2009 Forum Institute seminar on biosimilars, and the challenges involved in their successful development and launch. While the main focus of the meeting the biosimilars market in the EU, it was widely agreed that developments in the US, and President Obama's handling of the generic biotech issue, will be the defining issue of 2009 and beyond read more

Pfizer & Wyeth: opening the door for Big Pharma M&A

Pfizer's $68 billion move to acquire Wyeth has paved the way for further strategic realignments in the industry, as companies prepare for a raft of blockbuster patent expiries. In the wake of Pfizer's deal, Sanofi-Aventis has begun negotiations with banks in preparation for its own M&A activity while GlaxoSmithKline, still staying clear of mega-mergers, is making another round of job cuts read more

Online webcast: A better way to conduct alliance management

An exclusive webcast that brings together alliance managers to share their experiences in building and maintaining successful partnerships Listen now

Read all our partnering best practice articles.

Forthcoming events

Here are some of our suggested events for spring 2009:

BIO-Windhover 2009

New York, USA - April 13-15, 2009 - more details

Pharmaceutical Strategic Outlook 2009

The Grand Hyatt New York City, USA - April 13-15, 2009 - more details

CHI Alliance Management Congress

Boston, MA, USA - April 22-23, 2009 - more details

BIO International Convention 2009

Atlanta, GA, USA, May 18-21, 2009 - more details

Euro-Biotech Forum 2009

Barcelona, Spain, June 30 to July 1, 2009 - more details

View our full events calendar

People on the move

The following people have been reported on the move during February/March 2009:

Edward Stewart, Amar Singh, Michael Lytton,  Jeffery Vick to name just a few

read more about the latest people on the move

If you have news about a business development executive who is on the move - let us know

Partnering resources

Current Partnering maintains and regularly updates this list of useful resources for dealmakers across all industries.

The following topic areas are available - updated regularly:

• Partnering organizations
• Financing organizations
• Online Partnering
• Weblogs
• Mentoring/Networking
• Checklists
• Quotes
• Software Tools
• Library
• Journals
• Careers
• Training/education
• Other useful links
   

Missing something? Let us know and we will include all appropriate resources.

Contact us

Steve Poile, Editor

Web: http://www.CurrentPartnering.com

Mail: CurrentPartnering, Allanmere House, 6 Hobgate, York, YO24 4HF, United Kingdom

Tel: +44 7896 656732

Fax: +44 8703 305993

Email

Advertizing and sponsorship

CurrentPartnering offers several advertising options, enabling your product or service to be promoted to our global business development audience - further details available online.

or contact us to discuss your requirements.

About CurrentPartnering

CurrentPartnering is an online provider of best practice, business information and intelligence for dealmakers

• Reports
• Articles
• In the news
• Networks
• Scorecard
• Events
• On the move
• Careers
• Glossary
• Resources
• Advisers

Sponsored by:

CurrentPartnering reports

CurrentPartnering is a leading publisher of partnering business intelligence - for a full list of our latest publications visit the website at: www.currentpartnering.com   In additon, we list of publishers reports - see full list.